|
T3941 |
Choline Fenofibrate
|
Trilipix,ABT-335 |
P450
,
COX
,
PPAR
|
|
Choline Fenofibrate (Trilipix) is a choline formulation of fenofibrate, a synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. |
|
T25828 |
Monatepil maleate
|
AJ2615 maleate,AJ-2615 maleate,AJ 2615 maleate |
Calcium Channel
,
Adrenergic Receptor
,
Acyltransferase
|
|
Monatepil maleate (AJ-2615 maleate) is an orally active Ca2+-channel and α1-adrenoceptor antagonist and non-competitive heparanoyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with antihypertensive activity.Mo... |
|
T4628 |
Seladelpar
|
MBX 8025 |
PPAR
|
|
Seladelpar (MBX 8025) has been used in trials studying the treatment of Hyperlipidemia. |
|
T27832 |
Lifibrol
|
U 83860,K-12148,K-12.148,U-83860,K12148 |
Lipid
|
|
Lifibrol (U-83860) is an inhibitor of cholesterol synthesis.Lifibrol has anticholesterol and hypolipidemic properties and promotes the conversion of LDL Apo B-100 in patients with hypercholesterolemia and mixed hyperlipi... |
|
T24865 |
Tenivastatin
|
L-654969,L654969,Simvastatin acid,L 654969,Simvastatin hydroxy acid |
ROS
,
HMG-CoA Reductase
|
|
Tenivastatin (Simvastatin acid) is an anti-hyperlipidemic HMG-CoA reductase inhibitor that inhibits the production of reactive oxygen species (ROS) and can be used in the study of primary hyperlipidemia. |
|
T1162 |
Acipimox
|
Olbemox,K-9321 |
Others
|
|
Acipimox (K-9321) is a niacin derivative and nicotinic acid analog with activity as a hypolipidemic agent. Acipimox has special application for the treatment of hyperlipidemia in non-insulin-dependent diabetic patients. |
|
T1604 |
Tiratricol
|
3,3',5-Triiodothyroacetic acid |
Thyroid hormone receptor(THR)
|
|
Tiratricol (3,3',5-Triiodothyroacetic acid) is a metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of A... |
|
T27245L |
Eflucimibe
|
L0081,F-12511 |
Acyltransferase
|
|
Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidem... |
|
T67974 |
Berberine ursodeoxycholate
|
HTD1801,BUDCA |
|
|
Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.Berberine ursodeoxycholate has a wide range of metabolic activity and significantly red... |
|
T72025 |
PCSK9-IN-10
|
|
Serine/threonin kinase
|
|
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Li... |
|
T26819 |
Binifibrate
|
WAC104,WAC 104,Antopal,WAC-104,Biniwas |
|
|
Binifibrate is a hyperlipemiant drug used for the treatment of hyperlipidemia. |
|
T28825 |
Sodelglitazar
|
GW677954,GSK-677954 |
|
|
Sodelglitazar, a PPAR agonist, is used potentially for the treatment of hyperlipidemia and type 2 diabetes. |
|
T30110 |
AR 12456
|
AR12456,AR-12456 |
|
|
AR-12456 is a Trapidil derivative that prevents serum hyperlipidemia in guinea pigs. |
|
T23611 |
Acetiromate
|
Adecol |
|
|
Acetiromate is a drug of antilipidemic. It is used to treat hyperlipidemia. |
|
T28820 |
SMP-797 HCl
|
SMP-797,SMP 797,SMP797 |
|
|
SMP-797 HCl, an ACAT (acyl-CoA-cholesterol acyltransferase) inhibitor, is used potentially for the treatment of Hyperlipidemia. |
|
T38483 |
Omzotirome
|
TRC-150094 |
|
|
Omzotirome (TRC150094) is a functional analog of iodothyronines and holds potential for research on hyperlipidemia (WO2008149379). |
|
T11914 |
LY88074 Trimethyl ether
|
|
Others
|
|
LY88074 Trimethyl ether is useful for inhibiting various conditions associated with estrogen deprivation syndrome, such as osteoporosis and hyperlipidemia. |
|
T11913 |
LY88074 Methyl ether
|
|
Others
|
|
LY88074 Methyl ether is effective in inhibiting conditions associated with estrogen deprivation syndrome, such as osteoporosis and hyperlipidemia, which occur due to various estrogen-deficient states. |
|
T39122 |
Inclisiran
|
ALN-PCSsc |
|
|
Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) compound that effectively suppresses PCSK-9 transcription. It proves promising in the investigation of hyperlipidemia and cardiovascular disease (... |
|
T74754 |
FXR antagonist 2
|
|
|
|
Compound A-26, also known as FXR antagonist 2, is a diarylamide derivative that functions as a moderate FXR antagonist. It is utilized in researching hyperlipidemia and type 2 diabetes [1]. |
|
T11448 |
GOAT-IN-1
|
|
Others
|
|
|
|
T61430 |
S-2E
|
|
|
|
S-2E is a compound that functions as an orally active, noncompetitive inhibitor of both HMG-CoA reductase and acetyl-CoA carboxylase. It exhibits an anti-hyperlipidemic action, making it suitable for studying conditions ... |
|
T77113 |
Ongericimab
|
|
|
|
Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9 with demonstrated lipid-lowering efficacy. It is utilized in the research of hypercholesterolemia and hyperlipidemia [1]. |
|
T74876 |
GalNAc unconjugated/naked Inclisiran
|
|
|
|
Inclisiran (unconjugated/naked) is a double-stranded small interfering RNA (siRNA) that lacks GalNAc conjugation. This compound selectively inhibits the transcription of PCSK-9, making it applicable in the research of hy... |
|
T74248 |
AS-Inclisiran
|
|
|
|
Inclisiran (ALN-PCSsc), a double-stranded small interfering RNA (siRNA) compound, serves as the antisense of itself and targets PCSK-9 transcription inhibition. It is employed in the study of hyperlipidemia and cardiovas... |
|
T60764 |
PCSK9 modulator-4
|
|
|
|
PCSK9 modulator-4 (Compound 21) can be used in hyperlipidemia research that is a potent PCSK9 modulator (EC 50 = 0.15 nM). PCSK9 is a lowering low-density lipoprotein cholesterol (LDL-C) target that is recently validated... |
|
T60541 |
PCSK9 modulator-2
|
|
|
|
PCSK9 modulator-2 (Compound 1) is a potent PCSK9 modulator (EC 50 = 202 nM) that has the potential to be used in hyperlipidemia research. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a recently validated ther... |
|
T60646 |
PCSK9 modulator-3
|
|
|
|
PCSK9 modulator-3 (Compound 13) is a potent PCSK9 modulator with an EC 50 value of 2.46 nM that has the potential in the hyperlipidemia research. PCSK9 is a recently proved target for lowering low-density lipoprotein cho... |
|
T72889 |
FXR agonist 4
|
|
|
|
FXR agonist 4 with an EC 50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of ... |
|
T71306 |
Gemfibrozil-d6
|
|
|
|
Gemfibrozil-d6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil redu... |
|
T63515 |
THR-β agonist 4
|
|
|
|
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has shown research potential for metabolic diseases such as hyperlipidemia, obesity, hypercholesterolemia, diabetes and other conditions such as steatosis and... |
|
T63697 |
THR-β agonist 3
|
|
|
|
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has shown research potential for metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and... |
|
T79454 |
Anti-NASH agent 1
|
|
PPAR
|
|
Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α/δ agonist aimed at treating nonalcoholic steatohepatitis (NASH). At dosages of 3-10 mg/kg over four weeks, this compound ameliorates hy... |
|
T74583 |
Desmethylazelastine
|
|
|
|
Desmethylazelastine, the primary active metabolite of Azelastine, undergoes oxidative metabolism via the cytochrome P450 enzyme system, exhibits a 97% protein binding rate, and has an elimination half-life of 54 hours. A... |
